Komori
Asahi Intecc (7747) · PolicyAdvanced

Reviewing the Rationale for Cross-Shareholdings and Considering Sales

First written in FY2019. 2 of 5 entries say "Restated". Latest entry: FY2026.

5entries
8years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2019 – FY2021AdvancedFY2025 – FY20262019: 12020: 120202021: 120212022: 020222023: 020232024: 020242025: 120252026: 12026
Same theme, other companies
Review of the Rationale for Holding Strategic ShareholdingsA theme 1258 companies write about · 1 as a headwind · 666 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 1262 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「We acquired 1 unlisted equity security and sold 2 equity securities other than unlisted equity securities.」

    We continued our policy of verifying the rationale for cross-shareholdings. During the year, we acquired 1 unlisted equity security and sold 2 listed equity securities and other securities.
  2. FY2025AdvancedAnnual report

    「The company has determined that the purpose of holding its current cross-shareholdings is appropriate and that their holdings provide sufficient benefits even after taking the risks into account, meaning that the rationale for holding them is recognized. In addition, each year, the responsible department comprehensively assesses the significance and economic rationale of holding each cross-shareholding. For cross-shareholdings whose holding rationale is no longer recognized, the company considers selling them.」

    The company continued its policy of reviewing the rationale for cross-shareholdings. During the fiscal year, it acquired 1 unlisted shareholding and sold 1 shareholding. The holdings comprised 14 unlisted and 5 listed shareholdings.
  3. FY2021RestatedAnnual report

    「In addition, each year, the responsible department comprehensively assesses the significance and economic rationale of holding each cross-shareholding. For cross-shareholdings whose holding rationale is no longer recognized, the company considers selling them.」

    The company continues its policy of reviewing the rationale for cross-shareholdings, taking the cost of capital into account, and considering sales when the rationale is no longer recognized.
  4. FY2020RestatedAnnual report

    「In addition, each year, the responsible department comprehensively assesses the significance and economic rationale of holding each cross-shareholding. For cross-shareholdings whose holding rationale is no longer recognized, the company considers selling them.」

    The company continues its policy of reviewing the rationale for cross-shareholdings, taking the cost of capital into account, and considering sales when the rationale is no longer recognized.
  5. FY2019First statedAnnual report

    「Each year, the responsible department comprehensively assesses the significance and economic rationale of holding each cross-shareholding. For cross-shareholdings whose holding rationale is no longer recognized, the company considers selling them.」

    The company has, for the first time, disclosed as an independent topic its policy of reviewing the significance and economic rationale of cross-shareholdings each year, taking the cost of capital into account, and considering sales if the rationale is lost.
Moved together

"Global adoption of minimally invasive treatments, establishment of the ASAHI brand, and consolidated sales of ¥100 billion" moved the same way as this thread, in the same document, in 2 of its 5 moves.

222222★123456
  1. ★This thread
  2. 1Global adoption of minimally invasive treatments, establishment of the ASAHI brand, and consolidated sales of ¥100 billion2×
  3. 2Strengthening the global revenue base2×
  4. 3Expansion of Target Treatment Sites and Therapeutic Areas and Enhancement of Product Portfolio2×
  5. 4Driving Innovation by Strengthening Materials Research and Production Technology2×
  6. 5Strengthening regionally focused sales and marketing structures2×
  7. 6Expanding the Product Portfolio Through New Product Launches2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Asahi Intecc yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Reviewing the Rationale for Cross-Shareholdings and Considering Sales | ASAHI INTECC CO.,LTD. (7747) | Komori